Related Experiment Video
Updated: Apr 30, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.5K
Novel drug mechanisms in development for heart failure
Soidjon D Khodjaev1, John R Teerlink, Fady I Malik
1Section of Cardiology, San Francisco Veterans Affairs Medical Center, 111C, 4150 Clement Street, San Francisco, CA, 94121-1545, USA.
Pflugers Archiv : European Journal of Physiology
|May 6, 2014
Summary
Despite advances in heart failure therapy, patient mortality and morbidity remain high. This review focuses on novel heart failure drugs in clinical trials, offering new therapeutic mechanisms beyond current treatments.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure (HF) management has evolved significantly over 40 years.
- Current therapies include diuretics, digoxin, novel drugs, and devices with proven efficacy.
- Despite progress, substantial mortality and morbidity persist in heart failure patients.
Purpose of the Study:
- To provide an overview of investigative heart failure drugs.
- To highlight drugs with novel mechanisms of action currently in clinical trials.
- To identify potential future therapeutic strategies for heart failure.
Main Methods:
- Literature review of ongoing clinical trials for heart failure drugs.
- Focus on drugs with novel mechanisms of action.
- Synthesis of information on investigational therapies.
Main Results:
- Several new drugs with distinct mechanisms of action are under investigation.
- These agents represent potential advancements beyond current standard-of-care therapies.
- Ongoing clinical trials are evaluating the efficacy and safety of these novel agents.
Conclusions:
- There is a continued need for innovative heart failure therapies.
- Investigational drugs with novel mechanisms offer promising avenues for improved patient outcomes.
- The development of these new agents is crucial for addressing the unmet needs in heart failure treatment.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:30Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
01:22Heart Failure Drugs: Diuretics
1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
01:22Heart Failure Drugs: β-Blockers
2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:29Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K